Biosig Technologies (NASDAQ:STEX) Chairman Morgan Lee Lekstrom Buys 20,000 Shares

Posted by Mark Dietrich on Feb 19th, 2026

Biosig Technologies, Inc. (NASDAQ:STEX – Get Free Report) Chairman Morgan Lee Lekstrom acquired 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was purchased at an average price of $2.50 per share, with a total value of $50,000.00. Following the completion of the acquisition, the chairman owned 122,500 shares in the company, valued at $306,250. The trade was a 19.51% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Morgan Lee Lekstrom also recently made the following trade(s):

On Tuesday, February 3rd, Morgan Lee Lekstrom acquired 23,500 shares of Biosig Technologies stock. The shares were acquired at an average cost of $3.06 per share, for a total transaction of $71,910.00.
On Thursday, January 29th, Morgan Lee Lekstrom bought 2,500 shares of Biosig Technologies stock. The shares were bought at an average price of $3.70 per share, for a total transaction of $9,250.00.
On Monday, January 26th, Morgan Lee Lekstrom purchased 23,000 shares of Biosig Technologies stock. The stock was bought at an average price of $3.30 per share, with a total value of $75,900.00.
On Tuesday, January 27th, Morgan Lee Lekstrom acquired 5,500 shares of Biosig Technologies stock. The shares were bought at an average price of $3.12 per share, for a total transaction of $17,160.00.
On Friday, January 23rd, Morgan Lee Lekstrom bought 41,000 shares of Biosig Technologies stock. The stock was bought at an average price of $3.13 per share, for a total transaction of $128,330.00.

Biosig Technologies Stock Down 6.3%

NASDAQ:STEX opened at $2.38 on Thursday. The company has a market capitalization of $379.85 million, a price-to-earnings ratio of -1.76 and a beta of 1.50. Biosig Technologies, Inc. has a 12 month low of $0.40 and a 12 month high of $14.11.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings started coverage on Biosig Technologies in a research note on Friday, January 23rd. They set a “sell (d-)” rating for the company. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biosig Technologies presently has a consensus rating of “Sell”.

Check Out Our Latest Report on Biosig Technologies

About Biosig Technologies

(Get Free Report)

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.